Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616118 | 0.87 | PTGS2 (0.46) | PTGS2TLR8TLR7 | |
| SCHEMBL617914 | 0.84 | PTGS2 (0.44) | PTGS2 | |
| Dimethylamine SCHEMBL618459 | 0.82 | PRMT5 (0.44) | PTGS2 | |
| SCHEMBL615443 | 0.80 | PTGS2 (0.68) | PTGS2ALDH1A1 | |
| SCHEMBL617861 | 0.80 | PRKCZ (0.39) | PTGS2CYP11B1CYP11B2 | |
| SCHEMBL618456 | 0.78 | MAPK1 (0.52) | PTGS2MKNK1MKNK2ALDH1A1 | |
| SCHEMBL616536 | 0.78 | CCNC (0.39) | PTGS2CYP3A4CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL617915 | 0.77 | MKNK1 (0.40) | MKNK1MKNK2CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL618626 | 0.77 | MEN1 (0.43) | PTGS2CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL1168268 | 0.76 | MEN1 (0.44) | MKNK1MKNK2CYP19A1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966172-B1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2014-01-08 | — | — | EP | disclosed |
| EP-1966172-B1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20090270353-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN | 2009-10-29 | — | — | US | disclosed |
| US-7572821-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572821-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572821-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1966172-A1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Synta Pharmaceuticals Corporation (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-08-02 | — | — | US | disclosed |
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-08-02 | — | — | US | disclosed |
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-08-02 | — | — | US | disclosed |
| WO-2007061909-A1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061909-A1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | RB1, MKI67, MAPRE1 | PTGS2 3488/4885MKNK1 1248/4885MKNK2 1460/4885 |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS2 3488/4885MKNK1 1248/4885MKNK2 1460/4885 |
| US-20090270353-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS2 3488/4885MKNK1 1248/4885MKNK2 1460/4885 |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS2 3488/4885MKNK1 1248/4885MKNK2 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.